APOE Alleles With Tau and Aβ Pathology in Patients With Amyotrophic Lateral Sclerosis and Parkinsonism-Dementia Complex in the Kii Peninsula
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 16, 2021
- Accepted in final form July 11, 2022
- First Published September 21, 2022.
Article Versions
- Previous version (September 21, 2022 - 12:48).
- You are viewing the most recent version of this article.
Author Disclosures
- Ryogen Sasaki, MD, PhD,
- Satoru Morimoto, MD, PhD,
- Fumiko Ozawa,
- Hideyuki Okano, MD, PhD,
- Mari Yoshida, MD, PhD,
- Hiroyuki Ishiura, MD, PhD,
- Shoji Tsuji, MD,
- Shigeki Kuzuhara, MD, PhD and
- Yasumasa Kokubo, MD, PhD
- Ryogen Sasaki, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Satoru Morimoto, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Fumiko Ozawa,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Hideyuki Okano, MD, PhD,
(1) SanBio Co. Ltd; (2) K Pharma Co. Ltd.; (3) Kringle Pharma Inc.
NONE
None
(1) Inflammation and Regeneration, Editor-in-Chief, 2004~2022. (2) Stem Cell Reports, Editorial Board, 2017~2022. (3) Cell Stem Cell, Editorial Board, 2006~2022 (4) Genes to Cells, Associate Editor, 2008~2022
1. METHOD FOR PRODUCING ASTROCYTES, S Morimoto, Z Zhou, H Okano - US Patent App. 17/275,395, 2022. 2. Sample preparation system and method for electron microscope observation, plasma treatment apparatus, sputtering apparatus, and tape feeding mechanism used for sample preparation, S Shibata, T Shindo, H Okano, S Goto, US Patent App. 17/417,451, 2022. 3.METHOD FOR PRODUCING BRAIN ORGANOIDS, H Hiramine, M Ishikawa, H Okano, US Patent App. 17/293,355, 2022. 4. Suicide gene therapeutic agent for brain tumors using pluripotent stem cell, M Toda, H Okano, H Miyoshi, R Tamura, US Patent App. 16/765,257, 2022. 5.Treating Hearing Loss, A Edge, H Okano, M Fujioka, K Mizutari - US Patent App. 17/118,111, 2021.
NONE
NONE
NONE
NONE
NONE
NONE
(1)Takeda Pharmaceutical Company
(1) AMED, JP 22bm0804003, Principal Investigator, 2022
NONE
(1) Japanese Society for Regenerative Medicine (2) Japanese Society for Neurochemistry
(1) K Pharma Co. Ltd
(1) Sumitomo Pharmaceutical Co. Ltd
NONE
(1) SanBio Co. Ltd
NONE
NONE
- Mari Yoshida, MD, PhD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Hiroyuki Ishiura, MD, PhD,
None
NONE
(1) Speaker honoraria from Eisai Co., Ltd., FP Pharmaceutical Corporation, Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., UCB Japan Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd. (2) Speaker honoraria from Asian-Oceanian Myology Center and Korean Society of Medical Genetics and Genomics.
Editorial Board of Journal of Human Genetics (2020-) and Clinical Neurology (2021-).
Patents pending on genetic analysis of benign adult familial myoclonus epilepsy and CGG repeat expansion diseases.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Funds from the the Japan Society for the Promotion of Science (17H05085, 2017-2020; 18K19506, 2018-2020; and 20H03588 2020-2023).
NONE
Funds from the Kato Memorial Trust for Nambyo Research and Life Science Foundation of Japan.
NONE
NONE
NONE
NONE
NONE
NONE
- Shoji Tsuji, MD,
None
NONE
Ono Pharmaceutical Co. Ltd. Sanofi Novartis Japan Senju Pharmaceutical Co. Ltd.
NONE
NONE
NONE
NONE
Ono Pharmaceutical Co. Ltd.
NONE
NONE
NONE
Nobelpharma Co. Ltd.
The Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI [19H03425]), and the Japan Agency for Medical Research and Development (Grant-in-Aid [21ek0109491h0002]).
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Shigeki Kuzuhara, MD, PhD and
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Yasumasa Kokubo, MD, PhD
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) the Research Committee of CNS Degenerative Diseases (to YK, H29-Nanchi- Ippan-085, collaborator, 2017 - 2019) (2) the Research Committee of Muro Disease (Kii ALS/PDC) (to YK, 21210301, Chair, 2009-2014), by the Ministry of Health, Labor and Welfare (MHLW), Japan, (3) JSPS KAKENHI Grant Number (to YK, JP25305030, JP18KK0239, JP17H01689, JP18K07368, JP15J03921, JP19K17002, JP15K09364, JP18K07514, to SM, 19K17002, Chair, 2019–) (4) agrant-in-aid of the Research Consortium of Kii ALS/PDC from the Japan Agency for Medical Research and Development, AMED (to YK, 17ek0109139h0003, Chair, 2015-2017)
(1) the Mie Medical Fund, Japan (2) Japan Foundation for Neuroscience and Mental Health
None
NONE
NONE
NONE
NONE
NONE
NONE
- From the School of Nursing (R.S.), Suzuka University of Medical Science; Department of Physiology (S.M., F.O., H.O.), Keio University School of Medicine, Tokyo; Department of Oncologic Pathology (S.M.), School of Medicine, Mie University, Tsu; Department of Neuropathology (M.Y.), Institute for Medical Science of Aging, Aichi Medical University, Nagakute; Department of Neurology (H.I.), Graduate School of Medicine, the University of Tokyo; Department of Molecular Neurology (S.T.), Graduate School of Medicine, the University of Tokyo; Institute of Medical Genomics (S.T.), International University of Health and Welfare; Graduate School of Health Science and School of Nursing (S.K.), Suzuka University of Medical Science; and Kii ALS/PDC Research Center (Y.K.), Mie University, Graduate School of Regional Innovation Studies, Tsu, Japan.
- Correspondence
Dr. Kokubo ktyktykty{at}me.com
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan